

Figure 1

FIG. 1A.

VH sequence: (SEQ ID NO: 3)

GAAGTGCAGCTGGTGGAGTCTGGGGGAGGCTTAGTGAAGCCTGGAGGGTCCCTGAAACTC
TCCTGTGCAGCCTCTGGATTCAAGTTTAGTAGATATGCCATGTCTTGGGTTCGCCAGGCT
CCGGGAAGAGGCTGGAGTGGTGCACAACCATTAGTAGTGGTAGTTACATCTACTAT
CCAGACAGTGTGAAGGTCGATTCAACCATCTCCAGAGACAAATGTCAAGAACACCCCTGTAT
CTGCAAAATGAGCAGTCTGAGGCTCTGAGGACACGGCCATGTATTACTGTGCAAGACGAGAT
TAGGACCTGGACTACTTTGACTCCTGGGGCCAAAGCACCCCTGTCAACCGTCTCCTCA

VK sequence: (SEQ ID NO: 4)

GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCGGTGGGAGACAGAGTCACT
ATCACTTGCAAGCGAGTCGGGACATTAGAAGCTATTTAAACCTGGTACCAGCAGAAACCA
GGGAAAGCTCCTAAGACCCGTGATCTATTATGCAACAAGCTTGGCAGATGGGGTCCCGTCG
AGATTCAAGTGGCAGTGGATCTGGGCAAGATTATTCTCTCACCATCAGCAGCCTGGAGTCT
GACGATACAGCAACTTACTACTGTCTACAACATGGTGAGAGTCCATTACGGCTCGGCTCG
GGGACCAAGCTGGAATCAAA

FIG. 1B.

VH sequence: (SEQ ID NO: 1)

EVQLVESGGGLVKPGGSLKLSCAASGFKFSRYAMSWVRQAPGKRLEWVATISSGGSYIYY
PDSVKGRFTISRDNVKNLTLYLQMSSLRSEDAMYYCARRDYDLDFDSWGQGTLVTVSS

VK sequence: (SEQ ID NO: 2)

DIQMTQSPSSLSASVGDRVTITCKASRDIRS YLTWYQQKPGKAPKTLIYYATSLADGVPS
RFGSGSGQDYSLTISSLESDDTATYYCLQHGESPTLGSGTKLEIK

Figure 2

FIG. 2




Figure 3




Figure 3 (continued)





Figure 4

FIG. 4A




FIG. 4B




Figure 5

FIG. 5A

Group #	Group Size	Group Description	Disease Induction	Route	Dose Level	Dose Volume	Dose Regimen
1	N=5	Naive	N/A	N/A	N/A	N/A	N/A
2	N=10	Vehicle (PBS)	Sensitization with OVA/Alum via IP injection on day 0 and 14, and challenged with OVA in PBS intranasal on days 14, 25-27.	IP	N/A	200ul	Days 23, 25, and 27
3	N=11	Dexamethasone					
4	N=11	10D12				10ml/kg (200µl)	
5	N=11	10D12				200ul	
				IP	300ug	200ul	Days 23, 25, and 27

Figure 5 (continued)

FIG. 5B




FIG. 5C




Figure 6

FIG. 6A

Group #	Group Size	Group Description	Disease Induction	Dose Route	Dose Level	Volume Dosage	Dosing Regime
6	N=3	Naive	N/A	N/A	N/A	N/A	N/A
7	N=9	Vehicle Control	Sensitization with OVA/Alum via IP injection on day 0 and 14.	IP	N/A	200ul	Days -2, 1, 4, 7, 10, 13, and 16
8	N=9	CTLA-4-Ig		IP	300ug	200ul	
9	N=9	10D12		IP	60ug	200ul	
10	N=9	10D12		IP	300ug	200ul	

Figure 6 (continued)

FIG. 6B




FIG. 6C




Figure 7




Figure adapted from Gauthier et al., Am J Respir Crit Care Med. 2015 Sep 15; 192(6): 660–668, incorporate herein by reference in its entirety.